Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950896 | 0.87 | PTGER4 (0.42) | PTGER4NTRK1NTRK2HDAC1 | |
| SCHEMBL1626154 | 0.86 | PTGER4 (0.46) | PTGER4NTRK1NTRK2FAAHHDAC1 | |
| SCHEMBL3950900 | 0.85 | PTGER4 (0.42) | PTGER4NTRK1NTRK2FAAHHDAC1 | |
| SCHEMBL3950902 | 0.84 | RXRA (0.45) | PTGER4NTRK1NTRK2FAAHHDAC1 | |
| SCHEMBL3950753 | 0.83 | PTGER4 (0.44) | PTGER4NTRK1NTRK2FAAHHDAC1 | |
| SCHEMBL1626203 | 0.82 | FAAH (0.48) | PTGER4NTRK1NTRK2FAAHRXRA | |
| SCHEMBL27600058 | 0.81 | KDM4E (0.37) | PTGER4HDAC1MAPTDDAH1 | |
| SCHEMBL1623497 | 0.78 | PTGER4 (0.54) | PTGER4NTRK1NTRK2TP53 | |
| SCHEMBL30114861 | 0.76 | PTGER4 (0.62) | PTGER4NTRK1NTRK2TP53 | |
| SCHEMBL21470064 | 0.76 | PTGER4 (0.62) | PTGER4NTRK1NTRK2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | PTGER4 6/4885NTRK1 3135/4885NTRK2 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.